By Kashish Tandon (Reuters) -Indian drugmaker Anthem Biosciences' [ANTH.NS] $395 million IPO was fully subscribed on the ...

WeWork India had filed draft papers for the IPO in early February. The offer consists of 33 million equity shares held by ...

Shares of NTT DC REIT , a data centre real estate investment trust, were steady in its first full trading session on Tuesday, ...

U.S. publisher McGraw Hill is targeting a valuation of $4.2 billion in its IPO, the company said on Monday, joining other ...

First-day trading for Travel Food Services Limited, a joint venture with K Hospitality Corp., was weaker than both parties ...

Ben Gammell and Erik Zhou are building a CFO-CAO model grounded in trust, technical rigor and strategic clarity.

SAT to deliver verdict on NGO's appeal against Smartworks IPO over alleged non-disclosures; Sebi, company asked to file ...

Indira IVF Hospital is resuming its initial public offering (IPO) plans in India, potentially raising 35 billion rupees ($408 ...

The Lamtuf IPO will be a combination of fresh issue of 1 crore equity shares and an offer-for-sale of 20 lakh shares by ...

Carlsmed, a spine surgery solution company, announced today that it launched its initial public offering with the start of an ...

Anthem Biosciences' initial share sale received bids for 14,47,66,596 shares, as against 4,40,70,682 shares on offer, according to NSE data, translating into 3.28 times subscription.

The Rs 3,395 crore Initial Public Offering (IPO) of Anthem Biosciences, the Bangalore-based contract research, development, ...